Referred to the House Committee on Energy and Commerce.
Email me when HR 9661 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HR 9661. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The bill changes the Public Health Service Act so that, by default, companies seeking approval for biosimilar biological products will not have to conduct clinical studies on pharmacodynamics or comparative clinical efficacy. This affects drug manufacturers, the FDA, and patients who may see faster, lower‑cost access to biosimilars. The goal is to reduce development burdens while maintaining safety standards.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HR 9661
3 free questions a day, no accountHearings
- Full Committee Markup of Twenty-Nine Pieces of LegislationHouse Energy and Commerce · Jul 20, 2026
Sponsors
- Rep. Langworthy, Nicholas A. [R-NY-23] (R) · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HR 9661 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HR 9661 freeOr ask your AI assistant about HR 9661 directly:
Add to Claude, ChatGPT or Cursor